Poxel SA
7PO
Company Profile
Business description
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
Contact
259/261 Avenue Jean Jaures
Immeuble le Sunway
Lyon69007
FRAT: +33 437372010
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Major ASX miner reduces aluminium exposure
The Alcoa transaction unlocks value and sharpens ASX miners focus on base metals.
stocks
Vegemite owner’s shares remain expensive on normalising profits.
Australian dairy staple to see profits normalise with shares screening as overvalued.
stocks
Ask the analyst: Where does GYG stand following its US exit?
All roads lead back home for Guzman Y Gomez.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,037.00 | 11.20 | 0.12% |
| CAC 40 | 8,473.64 | 34.43 | -0.40% |
| DAX 40 | 25,795.03 | 15.72 | 0.06% |
| Dow JONES (US) | 52,816.07 | 84.00 | -0.16% |
| FTSE 100 | 10,630.42 | 48.61 | -0.46% |
| HKSE | 23,616.32 | 266.29 | 1.14% |
| NASDAQ | 26,125.54 | 292.87 | 1.13% |
| Nikkei 225 | 69,737.69 | 6.38 | -0.01% |
| NZX 50 Index | 13,763.10 | 144.68 | 1.06% |
| S&P 500 | 7,527.65 | 44.41 | 0.59% |
| S&P/ASX 200 | 8,831.00 | 12.70 | 0.14% |
| SSE Composite Index | 4,041.24 | 2.41 | -0.06% |